Skip to main content
OpenTrials
Completed

NCT Number: NCT07086157

Low-FODMAP Diet and Probiotics: Effects on Gut, Behavior, and Microbiota in Children With Autism Spectrum Disorder

The goal of this clinical trial was to evaluate whether a low-FODMAP diet and probiotic supplements could reduce gastrointestinal (GI) symptoms and behavior problems in children with autism spectrum disorder (ASD) who also experienced GI issues. The main questions it aimed to answer were:

Did a low-FODMAP diet and/or probiotics improve GI symptoms such as constipation, diarrhea, and abdominal pain?

Did these interventions help reduce behavior problems such as irritability, lethargy, stereotypy, hyperactivity, and speech disorder ?

Researchers compared two groups:

1. Children who received a daily probiotic supplement containing 4 strains for 4 weeks 2. Children who received both the probiotic supplement and followed a low-FODMAP diet

This comparison aimed to determine whether the combination of diet and probiotics had greater benefits than probiotics alone.

Participants:

Took the assigned intervention(s) for 4 weeks

Provided stool samples for gut microbiota analysis

Completed assessments of GI symptoms and behavior using validated questionnaires

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Marmara Univesity Pendik Training and Research Hospital

Istanbul, Turkey (Türkiye)

About this study

This randomized, controlled, parallel-group clinical trial aimed to investigate the effects of a low-FODMAP diet and multi-strain probiotic supplementation on gastrointestinal (GI) symptoms, behavioral problems, and gut microbiota composition in children with Autism Spectrum Disorder (ASD) who presented with concurrent GI complaints.

Children aged 6 to 12 years with clinically diagnosed ASD and GI symptoms were recruited. A total of 16 participants were randomly assigned into two equal groups (n=8 per group). One group received a probiotic supplement containing four bacterial strains daily for 4 weeks, while the second group received the same probiotic supplement in combination with a low-FODMAP diet over the same period. The randomization was stratified and allocation was blinded to the data analysts.

Interventions Probiotic group: A commercially available probiotic blend (containing Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus rhamnosus, and Saccharomyces boulardii) was administered once daily for 4 weeks.

Low-FODMAP + Probiotic group: In addition to the probiotic supplement, participants received individualized nutrition counseling and followed a standardized low-FODMAP diet protocol under dietitian supervision for 4 weeks.

Data Collection and Measures GI symptoms were assessed using the Pediatric Gastrointestinal Symptoms Questionnaire - Rome III Version (QPGS-RIII) and the Bristol Stool Scale (BSS).

Behavioral outcomes were evaluated using the Aberrant Behavior Checklist (ABC), focusing on subscales including irritability, lethargy-social withdrawal, stereotypy, hyperactivity, and inappropriate speech.

Dietary intake was recorded using 3-day food diaries to determine intake of daily FODMAP amount.

Microbiota composition was analyzed from fecal samples using 16S rRNA gene sequencing and LEfSe (Linear Discriminant Analysis Effect Size) for taxonomic biomarker discovery.

Quality Control and Data Validation All participants were monitored weekly to ensure adherence to interventions and assess adverse effects.

Dietary intake data were validated against food portion models and caregiver interviews.

Stool sample processing followed standardized protocols: DNA was extracted, amplified, and sequenced using Illumina platforms.

A pre-defined bioinformatics pipeline was used for quality filtering, taxonomic assignment, and alpha/beta diversity analysis.

Internal consistency checks and double data entry validation were applied to all behavioral and symptom questionnaires.

Statistical Analysis Statistical analysis was performed using SPSS v25 and R. Paired and independent-sample t-tests or Wilcoxon signed-rank tests were applied based on distribution normality. Microbiota diversity indices (Shannon, Simpson, Chao1) and taxonomic differences were compared across groups and time points. Spearman correlation analyses were used to explore associations between microbiota shifts and clinical parameters. A p-value of <0.05 was considered statistically significant.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with Autism Spectrum Disorder by a specialist at Marmara University Pendik Training and Research Hospital Child and Adolescent Psychiatry Clinic
  • Aged between 6 and 12 years
  • Diagnosed with functional gastrointestinal symptoms according to Rome IV criteria
  • Willing to participate by signing informed consent and assent forms (by both child and parent)

Exclusion criteria

  • Following any other dietary intervention at the time of study initiation
  • Routine use of prebiotics or probiotics
  • Use of antibiotics within the 4 weeks prior to the study
  • Presence of active diarrhea due to intestinal infection or similar condition
  • Diagnosis of other gastrointestinal diseases besides functional GI symptoms

Treatment and study plan

Probiotic

Dietary Supplement

A probiotic supplement in capsule form containing 4 strains of microorganisms, with a total of 10 × 10⁹ CFU (colony-forming units) per capsule. The strain composition per capsule was:

Lactobacillus acidophilus L1 - 2.9 × 10⁹ CFU, Bifidobacterium longum LBL-01 - 2.9 × 10⁹ CFU, Lactobacillus rhamnosus - 2.9 × 10⁹ CFU, Saccharomyces boulardii - 1.3 × 10⁹ CFU. Each participant in this arm took one capsule per day in the morning on a full stomach, for a duration of 4 weeks. No other dietary interventions were applied to this group. This probiotic supplement was chosen because the strains in its content are among the most frequently researched and known strains in terms of intestinal health. Additionally, it does not contain FOS or inulin due to FODMAP restriction.

.

Low-FODMAP diet

Other

A structured low-FODMAP diet intervention designed to restrict intake of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. The diet was individualized and monitored by a registered dietitian over a 4-week period to ensure adherence and nutritional adequacy.

Primary outcomes

  1. Change in Aberrant Behavior Checklist (ABC) Irritability Subscale Score

    Time frame: Baseline and after 4 weeks of intervention

    Change in caregiver-reported irritability scores as measured by the Aberrant Behavior Checklist Irritability Subscale, a standardized behavioral rating scale.

  2. Change in Aberrant Behavior Checklist (ABC) Hyperactivity Subscale Score

    Time frame: Baseline and after 4 weeks of intervention

    Change in hyperactivity scores, as assessed by the caregiver-completed Hyperactivity Subscale of the Aberrant Behavior Checklist (ABC), a standardized behavioral rating scale.

  3. Change in Aberrant Behavior Checklist (ABC) Lethargy-Social Withdrawal Subscale Score

    Time frame: Baseline and after 4 weeks of intervention

    Change in lethargy-social withdrawal scores, as assessed by the caregiver-completed Lethargy-Social Withdrawal Subscale of the Aberrant Behavior Checklist (ABC), a standardized behavioral rating scale.

  4. Change in Aberrant Behavior Checklist (ABC) Stereotypy Subscale Score

    Time frame: Baseline and after 4 weeks of intervention

    Change in stereotypy scores, as assessed by the caregiver-completed Stereotypy Subscale of the Aberrant Behavior Checklist (ABC), a standardized behavioral rating scale.

  5. Change in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score

    Time frame: Baseline and after 4 weeks of intervention

    Change in inappropriate speech scores, as assessed by the caregiver-completed Inappropriate Speech Subscale of the Aberrant Behavior Checklist (ABC), a standardized behavioral rating scale.

  6. Change in Presence of Functional Gastrointestinal Symptoms as Measured by the QPGS-RIII

    Time frame: Baseline and after 4 weeks of intervention

    Change in the presence of any functional gastrointestinal symptoms as determined by caregiver responses to the Pediatric Gastrointestinal Symptoms Questionnaire - Rome III (QPGS-RIII), a validated diagnostic tool for functional gastrointestinal disorders in children.

Secondary outcomes

  1. Change in Gut Microbiota Alpha Diversity (Shannon Index)

    Time frame: Baseline and after 4 weeks of intervention

    Change in microbial alpha diversity of stool samples, assessed using 16S rRNA gene sequencing and expressed as the Shannon diversity index.

  2. Change in Gut Microbiota Beta Diversity (UniFrac Analysis)

    Time frame: Baseline and after 4 weeks of intervention

    Change in microbial beta diversity of stool samples, assessed using 16S rRNA gene sequencing and analyzed with UniFrac distance metrics to evaluate differences in microbial community composition between samples.

  3. Change in Relative Abundance of Specific Bacterial Genera

    Time frame: Baseline and after 4 weeks of intervention

    Change in the relative abundance (%) of key bacterial genera identified through 16S rRNA sequencing and LEfSe analysis.

Sponsors and collaborators

Lead sponsor

Marmara University Pendik Training and Research Hospital

Other

Collaborators

  • Istanbul Saglik Bilimleri University

Registry information

Official study title

Effects of Low-FODMAP Diet and Probiotics on Gastrointestinal Symptoms, Behavior Problems, and Microbiota in Children With Autism Spectrum Disorder and Gastrointestinal Symptoms

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jul 25, 2025
Registry last updated
Jul 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.